CANSLIM Stock Screener – 2026-09-02 (111 Stocks)

Software-Application leads the day with 28 selections, followed by Software-Infrastructure at 20 and Oil & Gas Refining & Marketing at 8. Together these three industries account for over half of the 111 stocks that passed the CAN SLIM stock screener, indicating a clear tilt toward enterprise software names. The energy refining group, while smaller, still represents a meaningful secondary pocket of strength.

Seven stocks were confirmed by two or more screening criteria, marking them as the strongest cross-validated names: SNOW, BRZE, CRM, ETON, MDB, NET, and TEAM. This overlap suggests these issues exhibit multiple qualifying traits simultaneously, which typically raises their relative standing within the broader selection. Five new names joined the list versus the prior session — LPG, PAGP, RELY, REPX, and TAL — while CARL dropped out entirely.

Among the triple-confirmed names, only SNOW carries a detailed technical note. The stock is advancing within a rising wedge pattern, though its base is still immature at a depth of 6.5% and a formation period of just 2.6 weeks, with a pivot at $337.38. This early-stage structure implies the pattern has not yet had time to fully develop, which is a key consideration when assessing CANSLIM stocks. The shallow depth and short duration suggest the setup remains in its formative phase rather than a mature launch point.

For educational purposes only — not investment advice.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.